BiomX Inc. Files 8-K: Other Events Reported

TL;DR

BiomX filed an 8-K for 'Other Events' on Dec 8, 2025. Details TBD.

AI Summary

BiomX Inc. filed an 8-K on December 8, 2025, reporting an event under 'Other Events'. The company, formerly known as Chardan Healthcare Acquisition Corp. until April 30, 2018, is incorporated in Delaware and headquartered in Ness Ziona, Israel. The filing does not disclose specific details of the event but is a standard current report.

Why It Matters

This filing indicates a material event has occurred for BiomX Inc., requiring public disclosure. Investors should monitor for subsequent filings that may provide details on the nature of this event.

Risk Assessment

Risk Level: low — The filing is a routine 8-K for 'Other Events' without immediate disclosed financial or operational impact.

Key Players & Entities

• BiomX Inc. (company) — Registrant
• Chardan Healthcare Acquisition Corp. (company) — Former company name
• December 8, 2025 (date) — Date of report
• April 30, 2018 (date) — Date of former company name change

FAQ

Key Financial Figures

• $0.0001 — nge on which registered Common Stock, $0.0001 par value PHGE NYSE American Indi

Filing Documents

• ea0268807-8k_biomx.htm (8-K) — 29KB
• 0001213900-25-118969.txt ( ) — 192KB
• phge-20251208.xsd (EX-101.SCH) — 3KB
• phge-20251208_lab.xml (EX-101.LAB) — 33KB
• phge-20251208_pre.xml (EX-101.PRE) — 22KB
• ea0268807-8k_biomx_htm.xml (XML) — 4KB

01 Other Events

Item 8.01 Other Events. As previously reported, on November 25, 2025, BiomX Inc. ("BiomX" or the "Company") announced that an independent Data Monitoring Committee ("DMC") completed a safety review and recommended continuation of the Company's Phase 2b clinical trial (the "Study") that is designed to test the Company's drug candidate BX004 ("BX004") in treating Cystic Fibrosis ("CF") with an adjusted dosing regimen. On December 8, 2025, BiomX announced its discontinuation of the ongoing Study with CF associated with chronic Pseudomonas aeruginosa infections. After evaluating the projected timelines and resources required to proceed with an alternative dosing strategy as was recommended by the DMC, the Company determined that such requirements were beyond the Company's available resources, leading to the decision to discontinue the program. The Company is also taking cost-cutting measures, including a significant reduction of its workforce. Subject to availability of sufficient financial and other resources, BiomX will now focus on advancing its bacteriophage-based therapeutics, particularly BX011 for diabetic foot infections. Simultaneously, the Company is reviewing other strategic alternatives.

Forward-Looking Statements

Forward-Looking Statements This Current Report contains express or implied "forward-looking statements" within the meaning of the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: "target," "believe," "expect," "will," "may," "anticipate," "estimate," "would," "positioned," "future," and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. For example, when BiomX refers to its focus on BX011, implications of conducting a significant reduction of BiomX's workforce, sufficiency of financial and other resources, and potential strategic alternatives, it is using forward-looking statements. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on BiomX management's current beliefs, expectations and assumptions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of BiomX's control. These risks and uncertainties include, but are not limited to, changes in applicable laws or regulations; the possibility that BiomX may be adversely affected by other economic, business, and/or competitive factors, including risks inherent in pharmaceutical research and development, such as: adverse results in BiomX's drug discovery, preclinical and clinical development activities, the risk that the results of preclinical studies and early clinical trials may not be replicated in later clinical trials, BiomX's ability to enroll patients in its clinical trials, and the risk that any of its clinical trials may not commence, continue or be completed on time, or at all; decisions made by the FDA, and other regulatory authorities; decisions made by investigational review boards at clinical trial sites and publication

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BIOMX INC. December 8, 2025 By: /s/ Jonathan Solomon Name: Jonathan Solomon Title: Chief Executive Officer 2

View Full Filing

View this 8-K filing on SEC EDGAR